The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Key highlights of IMW 2021
Heinz Ludwig, MD, of the Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, outline the key sessions and topics discussed during the 18th International Myeloma Workshop (IMW) meeting. Prof. Ludwig talks on sessions covering the latest insights into the molecular mechanisms of myeloma, updated clinical trial data on the treatment of newly-diagnosed patients, as well as the importance of transplant. This interview took place during the IMW 2021 congress.
Disclosures
Heinz Ludwig, MD, has received research funding from Amgen and Takeda; and has received speaker’s honoraria and has participated in advisory boards for Amgen, Takeda, Sanofi, Janssen, Celgene-BMS and Seattle Genetics.
